Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Series on the Efficacy of Daratumumab in Treating Patients with Anti-Interferon-Gamma Autoantibodies.

Clinical and experimental immunology·2026
Same author

Performance evaluation of a CD34 expression assay by digital PCR in bone marrow harvest from healthy donors.

Transfusion·2026
Same author

Editorial Expression of Concern: DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation.

Nature immunology·2026
Same author

Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2026
Same author

Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors.

Annals of hematology·2026
Same author

PMMA/pPFPA membrane with low content of modified TiO<sub>2</sub> nanoparticles for effective retention of pharmaceuticals from water.

Scientific reports·2026
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Related Experiment Videos

The EUROclass trial: defining subgroups in common variable immunodeficiency.

Claudia Wehr1, Teemu Kivioja, Christian Schmitt

  • 1Department of Rheumatology and Clinical Immunology, University Clinic, Freiburg, Germany.

Blood
|September 28, 2007
PubMed
Summary
This summary is machine-generated.

Common Variable Immunodeficiency (CVID) classification was improved using B-cell phenotyping and clinical data. The EUROclass system identifies CVID subtypes based on B-cell levels, aiding in understanding disease mechanisms and patient risk.

Related Experiment Videos

Area of Science:

  • Immunology
  • Clinical Medicine
  • Flow Cytometry

Background:

  • Common Variable Immunodeficiency (CVID) exhibits significant heterogeneity, necessitating refined classification systems.
  • Existing classification schemes for CVID require consensus to better address pathogenic mechanisms and clinical relevance.
  • Flowcytometric B-cell phenotyping and clinical course are key parameters for CVID subtyping.

Purpose of the Study:

  • To develop a consensus classification for CVID by integrating existing schemes.
  • To correlate B-cell subpopulations with clinical manifestations in CVID patients.
  • To propose an improved classification system (EUROclass) for CVID based on B-cell phenotypes and clinical data.

Main Methods:

  • European multicenter trial involving 303 CVID patients.
  • Clinical evaluation and flowcytometric B-cell phenotyping.
  • Analysis of B-cell subpopulations including switched memory B cells, CD21(low) B cells, and transitional B cells.

Main Results:

  • Significant association found between granulomatous disease, autoimmune cytopenia, and splenomegaly in CVID patients.
  • Severe reduction in switched memory B cells observed in most patients, linked to increased risk of splenomegaly and granulomatous disease.
  • Expansion of CD21(low) B cells correlated with splenomegaly, while transitional B-cell expansion was linked to lymphadenopathy.

Conclusions:

  • The proposed EUROclass system categorizes CVID patients into distinct groups based on B-cell levels (absent, reduced switched memory, expanded transitional, or CD21(low) B cells).
  • This classification aids in identifying patients with severe B-cell differentiation defects and those with potential germinal center development issues.
  • Further research is needed to elucidate the underlying defects associated with expanded transitional and CD21(low) B cells in CVID.